BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 16403783)

  • 1. Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2.
    Warner TD; Vojnovic I; Bishop-Bailey D; Mitchell JA
    FASEB J; 2006 Mar; 20(3):542-4. PubMed ID: 16403783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs.
    Walter MF; Jacob RF; Day CA; Dahlborg R; Weng Y; Mason RP
    Atherosclerosis; 2004 Dec; 177(2):235-43. PubMed ID: 15530895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs.
    Giuliano F; Warner TD
    Br J Pharmacol; 1999 Apr; 126(8):1824-30. PubMed ID: 10372826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.
    Van Hecken A; Schwartz JI; Depré M; De Lepeleire I; Dallob A; Tanaka W; Wynants K; Buntinx A; Arnout J; Wong PH; Ebel DL; Gertz BJ; De Schepper PJ
    J Clin Pharmacol; 2000 Oct; 40(10):1109-20. PubMed ID: 11028250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers.
    Graff J; Skarke C; Klinkhardt U; Watzer B; Harder S; Seyberth H; Geisslinger G; Nüsing RM
    J Thromb Haemost; 2007 Dec; 5(12):2376-85. PubMed ID: 17916229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.
    Ouellet M; Riendeau D; Percival MD
    Proc Natl Acad Sci U S A; 2001 Dec; 98(25):14583-8. PubMed ID: 11717412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.
    Riendeau D; Charleson S; Cromlish W; Mancini JA; Wong E; Guay J
    Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological separation between peripheral and central functions of cyclooxygenase-2 with CIAA, a novel cyclooxygenase-2 inhibitor.
    Okumura T; Murata Y; Hizue M; Matsuura T; Naganeo R; Kanai Y; Murase A; Sakakibara A; Fujita I; Nakao K
    Eur J Pharmacol; 2006 Jun; 539(1-2):125-30. PubMed ID: 16690052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent.
    Harirforoosh S; Aghazadeh-Habashi A; Jamali F
    Clin Exp Pharmacol Physiol; 2006 Oct; 33(10):917-24. PubMed ID: 17002668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
    Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
    Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects.
    Panara MR; Renda G; Sciulli MG; Santini G; Di Giamberardino M; Rotondo MT; Tacconelli S; Seta F; Patrono C; Patrignani P
    J Pharmacol Exp Ther; 1999 Jul; 290(1):276-80. PubMed ID: 10381787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men.
    Tuleja E; Mejza F; Cmiel A; Szczeklik A
    Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1111-5. PubMed ID: 12730088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone.
    Wang BH; Bertucci MC; Ma JY; Adrahtas A; Cheung RY; Krum H
    Clin Exp Pharmacol Physiol; 2010 Sep; 37(9):912-8. PubMed ID: 20497423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.
    Brzozowski T; Konturek PC; Konturek SJ; Sliwowski Z; Pajdo R; Drozdowicz D; Ptak A; Hahn EG
    Microsc Res Tech; 2001 Jun; 53(5):343-53. PubMed ID: 11376495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COX-1 and COX-2 inhibitors.
    Hawkey CJ
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):801-20. PubMed ID: 11566042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of selective vs. non-selective cyclo-oxygenase inhibitors on fetal membrane prostaglandin synthesis.
    Sawdy R; Pan H; Sullivan M; Bennett P
    J Obstet Gynaecol; 2003 May; 23(3):239-43. PubMed ID: 12850850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
    Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F
    Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
    J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.
    Palomer A; Cabré F; Pascual J; Campos J; Trujillo MA; Entrena A; Gallo MA; García L; Mauleón D; Espinosa A
    J Med Chem; 2002 Mar; 45(7):1402-11. PubMed ID: 11906281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo effects of meloxicam and aspirin on blood, gastric mucosal, and synovial fluid prostanoid synthesis in dogs.
    Jones CJ; Streppa HK; Harmon BG; Budsberg SC
    Am J Vet Res; 2002 Nov; 63(11):1527-31. PubMed ID: 12428662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.